Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

CorMedix Inc. today announced that it has received CE Mark approval for Neutrolin, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced chronic kidney disease.

6 Jul 2013

Oncologist urges drug companies to include key information in cancer drug labels

In the July 10th issue of The New England Journal of Medicine, Dr. Basch calls for pharmaceutical manufacturers to collect rigorous information on how drugs impact symptoms and quality of life starting early in drug development, and for the U.S. Food and Drug Administration (FDA) to include this information in drug labels.

5 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

MGN1703 drug provides a new treatment approach to colorectal cancer

New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer.

4 Jul 2013

GAPVAC aims to develop personalized therapeutic vaccines for cancer

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

4 Jul 2013

Professor receives grant to explore therapeutic agent, treatment method for brain cancer

The problem with cancer treatments designed to kill a tumor is that they can kill the patient's quality of life as well. Now a Florida State University College of Medicine researcher is shifting the focus from eradicating brain tumors to managing them.

4 Jul 2013

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer.

4 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated.

3 Jul 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

UVA researchers identify promising target for treating glioblastoma

Researchers at the University of Virginia Cancer Center have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts to develop effective treatments for this deadliest of cancers.

2 Jul 2013

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex environment of the body.

2 Jul 2013

HDAC10 gene plays a key role in autophagy and resistance to chemotherapy in high-risk neuroblastomas

Neuroblastomas are pediatric tumors that originate from cells of the embryonic nervous system. The disease can take widely varying clinical courses that range from spontaneous regression to fatal outcomes.

2 Jul 2013

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Nano and laser technology packed into small device tests antibiotic treatment in minutes

Researchers at EPFL have built a matchbox-sized device that can test for the presence of bacteria in a couple of minutes, instead of up to several weeks. A nano-lever vibrates in the presence of bacterial activity, while a laser reads the vibration and translates it into an electrical signal that can be easily read-the absence of a signal signifies the absence of bacteria.

1 Jul 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Weekend reading: Chemo revolution, Lyme disease confusion and the residency mismatch

Because I've lived so long with anxiety, there were lots of things I figured I'd never, ever do - having children was one of them. In fact, in my 20s, before I'd managed to stumble on the combination of drugs and exercise that allows me to be as sane as I can expect to be, I was so sure I'd never give birth that I got a tattoo of a giant koi fish extending from one end of my abdomen to the other. ... I found myself in a very ironic situation: my decision to have a child was the result of a sense of stability I enjoyed due to taking an array of anti-anxiety medications that I would be strongly advised by most doctors to stop taking now that I was pregnant (Alissa Nutting, 6/23).

28 Jun 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

Oncologist urges drug companies to include key information in cancer drug labels

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

MGN1703 drug provides a new treatment approach to colorectal cancer

GAPVAC aims to develop personalized therapeutic vaccines for cancer

Professor receives grant to explore therapeutic agent, treatment method for brain cancer

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

UVA researchers identify promising target for treating glioblastoma

UNC scientists use GEMMs to develop biomarkers for molecular subtypes of human breast cancer

HDAC10 gene plays a key role in autophagy and resistance to chemotherapy in high-risk neuroblastomas

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Nano and laser technology packed into small device tests antibiotic treatment in minutes

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

Weekend reading: Chemo revolution, Lyme disease confusion and the residency mismatch

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in